Quantitative polymerase chain reaction (PCR) assay is commonly used to diagnose SARS CoV-2 or COVID-19, but it lacks the ability to account for mutations in the virus over time. SARS CoV-2 has mutated over 200 times since its initial breakout, and further mutations risk altering the gene-based detection "target", reducing the reliability of the test. In this scenario, mutated versions of the virus may not be detected and a second outbreak allowed to spike until the test is updated. Additionally, the binary nature of PCR assay does not allow automated data traceability, which is a critical component for building current and future outbreak prediction models.

JunoCOVID-DX : A viral testing platform with a rapid approach that enables reliable multiplexed detection of current and emerging viral strains and the ability to capture potential mutations. JunoCOVID-DX offers a simplified and non-invasive home-based or isolated sample collection kit.  The assay is fast, highly accurate, and offers high volume test (i.e. 96 tests in less than 10 minutes)